verapamil has been researched along with Ovarian Neoplasms in 60 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 7.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| " We determined the cytotoxicity of methotrexate and the lipid-soluble antifolate trimetrexate to various human carcinoma cells and their doxorubicin-resistant sublines." | 3.67 | Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. ( Assaraf, YG; Molina, A; Schimke, RT, 1989) |
| "Human ovarian cancer cell lines from drug resistant patients also has been demonstrated to increase levels of glutathione." | 2.37 | Multidrug resistance in ovarian cancer. ( Fojo, A; Hamilton, TC; Ozols, RF; Young, RC, 1987) |
| "Ovarian cancer is usually treated with transurethral resection or systemic chemotherapy in clinic." | 1.48 | Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer. ( Li, M; Lin, Y; Zhan, X; Zheng, W, 2018) |
| "Clinical response to chemotherapy for ovarian cancer is frequently compromised by the development of drug-resistant disease." | 1.43 | ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. ( Bray, SE; Chakravarty, P; Ferguson, MJ; Gannon, AL; Sawers, L; Scott, AL; Smith, G; Vaidyanathan, A, 2016) |
| "Our data suggest that ovarian cancer contain small sub-population of side population cells which shares some characteristics of stem cells." | 1.42 | Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer. ( Dou, HT; Liu, PS; Xu, P; Zhang, QH; Zhuang, SC, 2015) |
| "Verapamil was also inhibitory, indicating that gonadotropins activate calcium influx via L-type voltage-dependent calcium channels." | 1.36 | Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. ( Baxter, RC; Bolitho, C; Marsh, DJ; Mertens-Walker, I, 2010) |
| "Verapamil treatment did not reverse the intrinsic drug resistance of parental cells, but partially modulated the sensitivity of CABA-PTX cells to PTX and induced total sensitivity to vinblastine." | 1.32 | Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. ( Canevari, S; D'Ascenzo, S; Dolo, V; Millimaggi, D; Miotti, S; Pavan, A; Violini, S, 2004) |
| "D-Verapamil was only about half as toxic as racemic verapamil and this too is consistent with clinical observations." | 1.29 | Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. ( Bicknell, SR; Hamilton, T; Kaye, SB; Morrison, JG; Plumb, JA; Setanoians, A; Wishart, GC, 1994) |
| "Human ovarian cancer cell line SKOV3 was grown during a period of four months in the presence of increasing concentrations of cisplatin (25-100 ng/ml)." | 1.29 | P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. ( Pagé, M; Yang, X, 1995) |
| "Etoposide efflux may have been inhibited, not because of (competitive) inhibition by BSO or disturbance of the energy required for this process, but probably because of plasma membrane alterations." | 1.28 | Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines. ( Lafleur, MV; Lankelma, J; Mans, DR; Pinedo, HM; Retèl, J; Schuurhuis, GJ; Treskes, M, 1992) |
| "The sensitive/MDR human ovarian cancer cell line couple A2780/2780AD was used as a reference." | 1.28 | P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. ( Broxterman, HJ; Dekker, H; Lankelma, J; Schuurhuis, GJ; Spoelstra, EC, 1991) |
| "Verapamil was shown to be capable of increasing intracellular daunorubicin levels in normal lymphocytes isolated from patients undergoing chemotherapy for epithelial ovarian cancer." | 1.28 | Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy. ( Crowther, D; Fox, BW; McGown, AT; Murphy, D, 1991) |
| " The fact that enhancement was 6-10 fold greater in resistant then in sensitive cells, as well as the loss of biphasic properties of adriamycin on dose-response curves after combined treatment, indicate that cepharanthine may play a role in overcoming drug resistance in some tumor cells." | 1.28 | Enhancement of adriamycin cytotoxicity in sensitive and resistant sublines of human tumor cells by calcium antagonists. ( Mircheva, J; Tsuruo, T, 1990) |
| "Verapamil was found to enhance the cytotoxic effect of vincristine against ovarian cancer cells." | 1.28 | [In vitro drug-resistance decrease of ovarian cancer cells]. ( Lu, SM, 1990) |
| "Verapamil, that was demonstrated previously to enhance the cell-killing activity of PE immunotoxins, enhanced the activity of several ricin A chain immunotoxins, including 454A12-rRTA, 260F9-rRTA, and 454C11-RTA." | 1.27 | Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. ( FitzGerald, DJ; Pastan, I; Pirker, R; Willingham, MC, 1988) |
| "Eight patients with refractory ovarian cancer were treated on a pilot protocol of verapamil plus Adriamycin (Adria Laboratories, Columbus, OH)." | 1.27 | Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. ( Cunnion, RE; Hamilton, TC; Klecker, RW; Ostchega, Y; Ozols, RF; Parrillo, JE; Young, RC, 1987) |
| "Verapamil has been shown to reverse acquired drug resistance to Adriamycin (ADR) and vinblastine in the P388 leukemia and Ehrlich ascites carcinoma model systems." | 1.27 | Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. ( Cox, TC; Crowley, J; Goodman, GE; Yen, YP, 1987) |
| " The steep dose-response relationships in other lines support the rationale for high-dose therapy either by intraperitoneal or systemic administration of drugs." | 1.27 | Pharmacologic reversal of drug resistance in ovarian cancer. ( Ozols, RF, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (21.67) | 18.7374 |
| 1990's | 31 (51.67) | 18.2507 |
| 2000's | 9 (15.00) | 29.6817 |
| 2010's | 5 (8.33) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sako, M | 1 |
| Suzuki, H | 1 |
| Yamamoto, N | 1 |
| Hirota, K | 1 |
| Silva, GL | 1 |
| Cui, B | 1 |
| Chávez, D | 1 |
| You, M | 1 |
| Chai, HB | 1 |
| Rasoanaivo, P | 1 |
| Lynn, SM | 1 |
| O'Neill, MJ | 1 |
| Lewis, JA | 1 |
| Besterman, JM | 1 |
| Monks, A | 2 |
| Farnsworth, NR | 1 |
| Cordell, GA | 1 |
| Pezzuto, JM | 1 |
| Kinghorn, AD | 1 |
| Wang, W | 1 |
| Wan, Q | 1 |
| Li, M | 2 |
| Qu, F | 1 |
| Liu, H | 1 |
| Chen, Y | 1 |
| Marker, SC | 1 |
| King, AP | 1 |
| Swanda, RV | 1 |
| Vaughn, B | 1 |
| Boros, E | 1 |
| Qian, SB | 1 |
| Wilson, JJ | 1 |
| Yang, CH | 1 |
| Wang, C | 1 |
| Ojima, I | 1 |
| Horwitz, SB | 1 |
| Zheng, W | 1 |
| Lin, Y | 1 |
| Zhan, X | 1 |
| Zhang, QH | 1 |
| Dou, HT | 1 |
| Xu, P | 1 |
| Zhuang, SC | 1 |
| Liu, PS | 1 |
| Vaidyanathan, A | 1 |
| Sawers, L | 1 |
| Gannon, AL | 1 |
| Chakravarty, P | 1 |
| Scott, AL | 1 |
| Bray, SE | 1 |
| Ferguson, MJ | 1 |
| Smith, G | 1 |
| Mertens-Walker, I | 1 |
| Bolitho, C | 1 |
| Baxter, RC | 1 |
| Marsh, DJ | 1 |
| Yu, T | 1 |
| Hu, K | 1 |
| Bai, J | 1 |
| Wang, Z | 1 |
| Violini, S | 1 |
| D'Ascenzo, S | 1 |
| Millimaggi, D | 1 |
| Miotti, S | 1 |
| Canevari, S | 1 |
| Pavan, A | 1 |
| Dolo, V | 1 |
| Szotek, PP | 1 |
| Pieretti-Vanmarcke, R | 1 |
| Masiakos, PT | 1 |
| Dinulescu, DM | 1 |
| Connolly, D | 1 |
| Foster, R | 1 |
| Dombkowski, D | 1 |
| Preffer, F | 1 |
| Maclaughlin, DT | 1 |
| Donahoe, PK | 1 |
| Zhanping, W | 1 |
| Xiaoyu, P | 1 |
| Na, C | 1 |
| Shenglan, W | 1 |
| Bo, W | 1 |
| Rogan, AM | 1 |
| Hamilton, TC | 5 |
| Young, RC | 4 |
| Klecker, RW | 2 |
| Ozols, RF | 6 |
| Yano, S | 1 |
| Sone, S | 1 |
| Nishioka, Y | 1 |
| Naito, M | 1 |
| Tsuruo, T | 2 |
| Ogura, T | 1 |
| Alvarez, M | 1 |
| Paull, K | 1 |
| Hose, C | 1 |
| Lee, JS | 1 |
| Weinstein, J | 1 |
| Grever, M | 1 |
| Bates, S | 1 |
| Fojo, T | 1 |
| Spoelstra, EC | 3 |
| Westerhoff, HV | 2 |
| Pinedo, HM | 5 |
| Dekker, H | 3 |
| Lankelma, J | 8 |
| Guiral, M | 1 |
| Viratelle, O | 1 |
| Smellie, M | 1 |
| Kelland, LR | 3 |
| Thurston, DE | 1 |
| Souhami, RL | 1 |
| Hartley, JA | 1 |
| Sharp, SY | 1 |
| Rowlands, MG | 1 |
| Jarman, M | 1 |
| Plumb, JA | 1 |
| Wishart, GC | 1 |
| Setanoians, A | 1 |
| Morrison, JG | 1 |
| Hamilton, T | 1 |
| Bicknell, SR | 1 |
| Kaye, SB | 1 |
| Parekh, H | 1 |
| Simpkins, H | 1 |
| Aherne, GW | 1 |
| Hardcastle, A | 1 |
| Valenti, M | 1 |
| Bryant, A | 1 |
| Rogers, P | 1 |
| Pettit, GR | 1 |
| Srirangam, JK | 1 |
| Yang, X | 1 |
| Pagé, M | 1 |
| Elsinga, PH | 1 |
| Franssen, EJ | 1 |
| Hendrikse, NH | 1 |
| Fluks, L | 1 |
| Weemaes, AM | 1 |
| van der Graaf, WT | 1 |
| de Vries, EG | 1 |
| Visser, GM | 1 |
| Vaalburg, W | 1 |
| Harstrick, A | 1 |
| Vanhoefer, U | 2 |
| Schleucher, N | 1 |
| Schroeder, J | 1 |
| Baumgart, J | 1 |
| Scheulen, ME | 1 |
| Wilke, H | 1 |
| Seeber, S | 1 |
| Smeets, M | 1 |
| Raymakers, R | 1 |
| Vierwinden, G | 1 |
| Pennings, A | 1 |
| van de Locht, L | 1 |
| Wessels, H | 1 |
| Boezeman, J | 1 |
| de Witte, T | 1 |
| Gornati, D | 1 |
| Zaffaroni, N | 1 |
| Villa, R | 1 |
| De Marco, C | 1 |
| Silvestrini, R | 1 |
| Yin, MB | 1 |
| Guo, B | 1 |
| Voigt, W | 1 |
| Gibbs, JF | 1 |
| Skenderis, BS | 1 |
| Frank, C | 1 |
| Wrzosek, C | 1 |
| Rustum, YM | 1 |
| Choi, SU | 1 |
| Park, SH | 1 |
| Kim, KH | 1 |
| Choi, EJ | 1 |
| Kim, S | 1 |
| Park, WK | 1 |
| Zhang, YH | 1 |
| Kim, HS | 1 |
| Jung, NP | 1 |
| Lee, CO | 1 |
| Posypanova, GA | 1 |
| Shmyrev, II | 1 |
| Rodina, AV | 1 |
| Muizhnek, EL | 1 |
| Severin, ES | 1 |
| Luzhkov, YM | 1 |
| Severin, SE | 1 |
| Duan, Z | 1 |
| Feller, AJ | 1 |
| Penson, RT | 1 |
| Chabner, BA | 1 |
| Seiden, MV | 1 |
| Schuldes, H | 1 |
| Dolderer, JH | 1 |
| Zimmer, G | 1 |
| Knobloch, J | 1 |
| Bickeböller, R | 1 |
| Jonas, D | 1 |
| Woodcock, BG | 1 |
| Meng, J | 1 |
| You, Z | 1 |
| Guo, Y | 1 |
| Liao, M | 1 |
| Chen, H | 2 |
| Shui, H | 1 |
| Alfonso-De Matte, MY | 1 |
| Moses-Soto, H | 1 |
| Kruk, PA | 1 |
| Aird, RE | 1 |
| Cummings, J | 1 |
| Ritchie, AA | 1 |
| Muir, M | 1 |
| Morris, RE | 1 |
| Sadler, PJ | 1 |
| Jodrell, DI | 1 |
| Mans, DR | 1 |
| Schuurhuis, GJ | 5 |
| Treskes, M | 1 |
| Lafleur, MV | 1 |
| Retèl, J | 1 |
| Wasserman, L | 1 |
| Aviram, R | 1 |
| Levavi, H | 1 |
| Ovadia, J | 1 |
| Shneyuor, Y | 1 |
| Frisch, A | 1 |
| Blau, O | 1 |
| Beery, E | 1 |
| Novogrodsky, A | 1 |
| Nordenberg, J | 1 |
| Mutch, DG | 1 |
| Herzog, TJ | 1 |
| Chen, CA | 1 |
| Collins, JL | 1 |
| Broxterman, HJ | 5 |
| Mizuno, K | 1 |
| Furuhashi, Y | 1 |
| Maeda, O | 1 |
| Iwata, M | 1 |
| Misawa, T | 1 |
| Kawai, M | 1 |
| Kano, T | 1 |
| Tomoda, Y | 1 |
| McGown, AT | 1 |
| Murphy, D | 1 |
| Crowther, D | 1 |
| Fox, BW | 1 |
| Hendrick, AM | 1 |
| Harris, AL | 1 |
| Cantwell, BM | 1 |
| Mircheva, J | 1 |
| Lu, SM | 1 |
| Assaraf, YG | 1 |
| Molina, A | 1 |
| Schimke, RT | 1 |
| Bénard, J | 1 |
| Da Silva, J | 1 |
| Teyssier, JR | 1 |
| Riou, G | 1 |
| Pirker, R | 2 |
| FitzGerald, DJ | 2 |
| Willingham, MC | 2 |
| Pastan, I | 2 |
| Fojo, A | 1 |
| Kuiper, CM | 1 |
| Kaptein, LC | 1 |
| van der Hoeven, JJ | 1 |
| Cunnion, RE | 1 |
| Ostchega, Y | 1 |
| Parrillo, JE | 1 |
| Goodman, GE | 1 |
| Yen, YP | 1 |
| Cox, TC | 1 |
| Crowley, J | 1 |
| Gibby, EM | 1 |
| Boyse, O | 1 |
| Hill, BT | 1 |
1 review available for verapamil and Ovarian Neoplasms
| Article | Year |
|---|---|
Multidrug resistance in ovarian cancer.
Topics: DNA Repair; Doxorubicin; Drug Resistance; Female; Gene Amplification; Glutathione; Humans; Ovarian N | 1987 |
2 trials available for verapamil and Ovarian Neoplasms
| Article | Year |
|---|---|
Reversal of adriamycin resistance by verapamil in human ovarian cancer.
Topics: Cell Line; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; | 1984 |
Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feasibility Studies; Female; | 1991 |
57 other studies available for verapamil and Ovarian Neoplasms
| Article | Year |
|---|---|
Highly increased cellular accumulation of vincristine, a useful hydrophobic antitumor-drug, in multidrug-resistant solid cancer cells induced by a simply reduced taxinine.
Topics: Antineoplastic Agents, Phytogenic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synerg | 1999 |
Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Crystal | 2001 |
Design, synthesis and biological evaluation of seco-DSP/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780/T cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2023 |
Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Coordination | 2020 |
Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Drug Resistance, | 2018 |
Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Delivery Syste | 2018 |
Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer.
Topics: Antigens, CD; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2015 |
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; | 2016 |
Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}.
Topics: Acetophenones; Benzopyrans; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cell Movement; Cell | 2010 |
Reversal of adriamycin resistance in ovarian carcinoma cell line by combination of verapamil and low-level ultrasound.
Topics: Antineoplastic Agents; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intrac | 2003 |
Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Div | 2004 |
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; CHO Cells; | 2006 |
Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell.
Topics: 4-Aminopyridine; Calcium; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Ovari | 2007 |
Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; ATP Binding Cas | 1994 |
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Surv | 1995 |
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Carcinoma, No | 1994 |
Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transpor | 1994 |
Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents.
Topics: Anthramycin; Antibiotics, Antineoplastic; Benzodiazepines; Cross-Linking Reagents; DNA Damage; DNA, | 1994 |
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calmodulin; Cisplatin; Doxorubicin; Drug Resistance; | 1994 |
Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
Topics: Animals; Calcium Channel Blockers; Doxorubicin; Drug Resistance; Drug Synergism; Epirubicin; Female; | 1994 |
Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine | 1996 |
Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Division; Colonic Neoplasms; Cross Reactions; Depsip | 1996 |
P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Doxorubic | 1995 |
Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbo | 1996 |
Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplas | 1995 |
A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity.
Topics: Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Cell Di | 1997 |
Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blotting, Northern; Calcium Channel Blocke | 1997 |
Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channe | 1998 |
The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Alpha-fetoprotein-mediated targeting--a new strategy to overcome multidrug resistance of tumour cells in vitro.
Topics: alpha-Fetoproteins; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Memb | 1997 |
Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Topics: Breast Neoplasms; Chemokine CCL2; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Female | 1999 |
Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts.
Topics: Animals; Antineoplastic Agents; Cell Division; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Doxorub | 2001 |
[Effects of estradiol and medroxyprogesterone on the growth and doxorubin-resistance of drug-resistant human epithelial ovarian cancer cell line OVCAR-3].
Topics: Cell Division; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Female; Genes, MDR; Humans; Medrox | 1999 |
[Apoptosis induced by cisplatin and verapamil or SDZ PSC 833 in human ovarian cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; | 2000 |
Calcium-mediated telomerase activity in ovarian epithelial cells.
Topics: Cadmium; Calcium; Cell Transformation, Neoplastic; Cells, Cultured; Chromium; Epithelial Cells; Fema | 2002 |
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2002 |
Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma, Non-Small-Cell | 1992 |
A cell line with unusual characteristics from an ovarian carcinoma patient: modulation of sensitivity to antitumour drugs.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 1992 |
The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin.
Topics: Antimetabolites, Antineoplastic; Buthionine Sulfoximine; Cell Death; Cisplatin; Cycloheximide; Cyclo | 1992 |
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transpor | 1991 |
Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cystadenocarcinoma; DNA, Neop | 1990 |
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Daunorubicin; | 1990 |
Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy.
Topics: Daunorubicin; Epithelium; Female; Humans; Lymphocytes; Ovarian Neoplasms; Time Factors; Verapamil | 1991 |
Enhancement of adriamycin cytotoxicity in sensitive and resistant sublines of human tumor cells by calcium antagonists.
Topics: Alkaloids; Benzylisoquinolines; Calcium Channel Blockers; Dose-Response Relationship, Drug; Doxorubi | 1990 |
[In vitro drug-resistance decrease of ovarian cancer cells].
Topics: Cisplatin; Cystadenocarcinoma; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Fe | 1990 |
Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Cell Line; Cyclosporins; Daunorubicin; Drug Resista | 1990 |
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Gen | 1989 |
Over-expression of MDR1 gene with no DNA amplification in a multiple-drug-resistant human ovarian carcinoma cell line.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromosome Deletion; Dactinomycin; Doxorubicin; Drug | 1989 |
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines.
Topics: ADP Ribose Transferases; Bacterial Toxins; Breast Neoplasms; Cell Line; Cell Survival; Colony-Formin | 1985 |
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines.
Topics: ADP Ribose Transferases; Bacterial Toxins; Cadaverine; Calmodulin; Carcinoma, Squamous Cell; Cell Li | 1988 |
Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells.
Topics: Adenosine Triphosphate; Animals; Daunorubicin; Drug Resistance; Female; Humans; Hydrolysis; Osmolar | 1988 |
Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.
Topics: Bepridil; Calcium Channel Blockers; Calmodulin; Cell Line; Doxorubicin; Drug Resistance; Drug Synerg | 1987 |
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Drug Resistance; Female | 1987 |
Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells.
Topics: Breast Neoplasms; Cell Survival; Clone Cells; Colonic Neoplasms; Doxorubicin; Drug Resistance; Esoph | 1987 |
Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.
Topics: Cell Survival; Colony-Forming Units Assay; Doxorubicin; Drug Interactions; Female; Humans; Mitoxantr | 1987 |
Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications.
Topics: Animals; Buthionine Sulfoximine; Cell Line; Doxorubicin; Drug Resistance; Drug Synergism; Female; Gl | 1986 |
Pharmacologic reversal of drug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Cell Line; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Res | 1985 |